Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes
- PMID: 33128843
- PMCID: PMC7754002
- DOI: 10.1111/jcmm.15742
Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes
Abstract
Psoriasis and psoriatic arthritis are multifactorial chronic disorders whose etiopathogenesis essentially derives from the alteration of several signalling pathways and the co-occurrence of genetic, epigenetic and non-genetic susceptibility factors that altogether affect the functional and structural property of the skin. Although shared and differential susceptibility genes and molecular pathways are known to contribute to the onset of pathological phenotypes, further research is needed to dissect the molecular causes of psoriatic disease and its progression towards Psoriatic Arthritis. This review will therefore be addressed to explore differences and similarities in the etiopathogenesis and progression of both disorders, with a particular focus on genes involved in the maintenance of the skin structure and integrity (keratins and collagens), modulation of patterns of recognition (through Toll-like receptors and dectin-1) and immuno-inflammatory response (by NLRP3-dependent inflammasome) to microbial pathogens. In addition, special emphasis will be given to the contribution of epigenetic elements (methylation pattern, non-coding RNAs, chromatin modifiers and 3D genome organization) to the etiopathogenesis and progression of psoriasis and psoriatic arthritis. The evidence discussed in this review highlights how the knowledge of patients' clinical and (epi)genomic make-up could be helpful for improving the available therapeutic strategies for psoriasis and psoriatic arthritis treatment.
Keywords: C. Albicans; (epi)genomics; Psoriasis; Psoriatic Arthritis; anti-fungine response; collagens; inflammation; keratins; skin disorders.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Conflict of interest statement
The authors confirm that there are no conflict of interest.
Figures


Similar articles
-
Psoriatic arthritis: a clinical entity distinct from psoriasis?Rev Bras Reumatol. 2012 Aug;52(4):630-8. Rev Bras Reumatol. 2012. PMID: 22885427 Review. English, Portuguese.
-
Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV).Sci Rep. 2020 Mar 18;10(1):4925. doi: 10.1038/s41598-020-61981-5. Sci Rep. 2020. PMID: 32188927 Free PMC article.
-
Skin and bone: the pathogenetic relationship between psoriasis and psoriatic arthritis.G Ital Dermatol Venereol. 2010 Jun;145(3):393-406. G Ital Dermatol Venereol. 2010. PMID: 20461047 Review.
-
Clinical presentation of psoriatic arthritis.Reumatismo. 2007;59 Suppl 1:49-51. doi: 10.4081/reumatismo.2007.1s.49. Reumatismo. 2007. PMID: 17828344
-
Differences between psoriatic arthritis and psoriasis in multi-omics.Arch Dermatol Res. 2024 May 24;316(6):217. doi: 10.1007/s00403-024-03018-9. Arch Dermatol Res. 2024. PMID: 38787526 Review.
Cited by
-
The Molecular Pathophysiology of Psoriatic Arthritis-The Complex Interplay Between Genetic Predisposition, Epigenetics Factors, and the Microbiome.Front Mol Biosci. 2021 Apr 1;8:662047. doi: 10.3389/fmolb.2021.662047. eCollection 2021. Front Mol Biosci. 2021. PMID: 33869291 Free PMC article. Review.
-
Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study.Acta Derm Venereol. 2021 Sep 15;101(9):adv00545. doi: 10.2340/00015555-3846. Acta Derm Venereol. 2021. PMID: 34043021 Free PMC article.
-
The Role of Epigenetic Factors in Psoriasis.Int J Mol Sci. 2021 Aug 27;22(17):9294. doi: 10.3390/ijms22179294. Int J Mol Sci. 2021. PMID: 34502197 Free PMC article. Review.
-
New Insights on Juvenile Psoriatic Arthritis.Front Pediatr. 2022 May 26;10:884727. doi: 10.3389/fped.2022.884727. eCollection 2022. Front Pediatr. 2022. PMID: 35722498 Free PMC article. Review.
-
Clinical Application of Pharmacogenetic Markers in the Treatment of Dermatologic Pathologies.Pharmaceuticals (Basel). 2021 Sep 6;14(9):905. doi: 10.3390/ph14090905. Pharmaceuticals (Basel). 2021. PMID: 34577605 Free PMC article. Review.
References
-
- Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134:1527‐1534. - PubMed
-
- Bergboer JGM, Zeeuwen PLJM, Irvine AD, et al. Deletion of late cornified envelope 3B and 3C genes is not associated with atopic dermatitis. J Invest Dermatol. 2010;130:2057‐2061. - PubMed
-
- Cascella R, Foti Cuzzola V, Lepre T, et al. Full sequencing of the FLG gene in Italian patients with atopic eczema: evidence of new mutations, but lack of an association. J Invest Dermatol. 2011;131:982‐984. - PubMed
-
- Cascella R, Strafella C, Germani C, et al. FLG (filaggrin) null mutations and sunlight exposure: evidence of a correlation. J Am Acad Dermatol. 2015;73:528‐529. - PubMed
-
- Lepre T, Cascella R, Ragazzo M, et al. Association of KIF3A, but not OVOL1 and ACTL9, with atopic eczema in Italian patients: KIF3A is a susceptibility gene for atopic eczema in the Italian population. Br J Dermatol. 2013;168:1106‐1108. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical